|
|
Dr. Grubbs is a world-renowned 2005 Nobel Laureate, Professor of Chemistry at Caltech. Dr. Grubbs has received numerous professional fellowships and awards and is also a member of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences. He is also a founder, director, or advisor to numerous technology companies, including Contour Energy Systems, Materia, Cyrano Sciences, Insert Therapeutics, Calhoun Vision, and Novomer. In addition, he is a member of the Reliance Innovation Council, and of the Industry Advisory Group at Zouk Ventures Ltd and at Cleantech Europe. Dr. Grubbs is also the California Institute of Technology's Victor and Elizabeth Atkins Professor of Chemistry since 1978.
|
Dr. Argeris ("Jerry") Karabelas is a Partner at Care Capital, a life sciences venture capital firm with $500 million under management. Jerry currently serves as Chairman of the Board for several of Care Capital's portfolio companies, including Vanda Pharmaceuticals, NitroMed Pharmaceuticals, Cyreniac Pharmaceuticals and Inotek Pharmaceuticals, and he also serves as a Director for Minster Pharmaceuticals. In addition to these board positions, Jerry also serves as Chairman of Human Genome Sciences and as a Non-Executive Director for SkyePharma. He had previously served on the board of several other companies, including Renovo, Anadys Pharmaceuticals, Acura Pharmaceuticals, and the Fox Chase Cancer Center. Prior to Care Capital, Jerry was the Founder and Chairman of the Novartis BioVenture Fund. In this role he invested approximately $40 million in 14 portfolio companies. From 1998 to 2000, Jerry was Head of Healthcare and CEO of Worldwide Pharmaceuticals for Novartis AG. He had full responsibility for Novartis Pharma, Ciba Vision and Generics representing $12 billion in annual sales. Included in these responsibilities was strategic and operational leadership of R&D with a budget in excess of $2 billion. Prior to joining Novartis, Jerry was Executive Vice President of SmithKline Beecham responsible for US operations, European operations, Regulatory, and Strategic Marketing. He has been responsible for numerous pharmaceutical product approvals and new products launches, including the launch of four $1 billion products. Jerry holds a Ph.D. in Pharmacokinetics from the Massachusetts College of Pharmacy. He is a member of the Visiting Committee for Health Sciences and Technology at MIT.
|
Dr Diekman, Ph.D. is a founder and Managing Partner of 5AM Ventures. Prior to founding 5AM, Dr. Diekman was a founder and Managing Director of Bay City Capital, a life sciences investment firm. Previously, Dr. Diekman was Chairman and CEO of Affymetrix, Inc, where he still serves as a Director. Dr. Diekman currently serves as Board Chairman of Ambrx and Phenomix as well as on the Boards of Directors of Igenica, Ingenuity Systems, Marcadia, PhaseRx and Wildcat Discovery. Dr. Diekman was the Vice-Chairman of Singapore's Life Science Fund, Bio*One Capital and he currently serves as advisor. He was recently named a Trustee of Princeton University and is also former Trustee of The California Institute of Technology and The Scripps Research Institute, where he served as Chairman. Dr. Diekman holds a B.A. in Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University.
|
Michael D. Laufer, M.D., is the founder of more than fifteen medical companies and his inventions are the subject of over 200 issued or in process patents. He is the Founder of Asthmatx, Inc. Dr. Laufer is also the Founder and past or present Director of VNUS Medical Technologies, Broncus Technologies and several other private companies. He was the Medical Director of Emergency Medicine at UCSF Mount Zion Medical Center in San Francisco, and is a member of the academic and clinical faculty at Stanford University, and of Harvard Medical School. He is a founding partner of MachLabs,LP, a venture capital firm. Dr. Laufer is a graduate of the University of Colorado, B.S. in Biological Sciences - MCDB, with distinction, and the Stanford University School of Medicine, M.D. He completed his emergency medicine residency at Harbor-UCLA and did a post-graduate fellowship at Stanford University Medical Center.
|
Mr Teng is the founder of Target Asset Management Pte Ltd. Since its inception in April 1996, he has served as the Chief Executive and Chief Investment Officer of the company. Prior to that, Mr Teng held many senior positions in the fund management industry including the Managing Director of Morgan Grenfell Investment Management (Asia) Limited, an Executive Director of UBS Investment Management Pte Ltd and the Chief Executive Officer of Prime Partners Asset Management Group. During his previous appointments, Mr Teng was instrumental in launching a direct investment fund investing in Asia and several country funds investing in Indonesia, China, Pakistan and Korea. Before joining the fund management industry, Mr Teng worked for several listed industrial companies in Singapore and Malaysia, holding various positions including Financial Controller and Group General Manager.; Mr Teng is an accountant by training. He is a member of the Chartered Association of Certified Accountant (UK), Institute of Chartered Secretaries and Administrator (UK) and Institute of Certified Public Accountants, Singapore. He was a council member of the Singapore Society of Financial Analysts between 1992 and 2002
|
|
|